Clinical Trials Logo

Clinical Trial Summary

Verruca plana is a common skin infection with worldwide distribution. Approximately 10% of general population is infected with flat warts and it represents up to 18 % of the patients seeking treatment for warts. Verruca plana is not merely an infectious disease but also affects the quality of patients' life. Verruca plana causes major cosmetic and social concerns. Lesions' persistence and recurrence cause frustrations and psychological distress which motivate patients to seek different treatment strategies. Verruca plana commonly affects the school aged children which augments its effect on the psychological and social development of children with stigmatization and bullying are great risks. The available treatment strategies neither ensured complete clearance of the disease nor were free of side effects. Frequently used physical removal methods are operator dependent and commonly lead to irritation, local inflammation, scars, dyspigmentation, and disfigurement. In this study we evaluate the efficacy and the safety of tazarotene gel 0.1% in the treatment of verruca plana compared to imiquimod or 5-fluorouracil


Clinical Trial Description

Patients will be assigned randomly into one of 4 groups as 1:1:1:1 using randomization.com with the seed number 7607 - Group (A): Patients will be treated with topical tazarotene gel 0.1%with a cotton tipped applicator on every lesion once daily at night. - Group (B): Patients will be treated with topical 5- fluorouracil 5% cream applied once daily at night. - Group (C): Patients will be treated with imiquimod cream 5% applied once daily at night. - Group (D): Patients will be treated with petroleum jelly once daily at night. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05314127
Study type Interventional
Source Zagazig University
Contact Hagar Nofal, Dr.
Phone 01006387707
Email hagarnofal@aucegypt.edu
Status Recruiting
Phase Phase 2
Start date April 15, 2022
Completion date December 2022